SAT1 and prostate cancer: In addition, the authors observed that SSAT was overexpressed in locally invasive prostate cancer patients with PSAs larger than 10 ng/mL and patients with poor prognosis (i.e., PSA increase after surgery, lymph node involvement, and metastasis) [19].